Interaction of FABP4 with plasma membrane proteins of endothelial cells;Interacción de FABP4 con proteínas de membrana de células endoteliales

Clinica e Investigacion en Arteriosclerosis

Volumn 27, Issue 1, 2015, Pages 26-33

  Saavedra, Paula ^a   Girona, Josefa ^a   Aragonès, Gemma ^a   Cabré, Anna ^a   Guaita, Sandra ^a   Heras, Mercedes ^a   Masana, Lluís ^a  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

Author keywords

Endothelial cells; FABP4; Plasma membrane; Receptor

Indexed keywords

CD31 ANTIGEN; FATTY ACID BINDING PROTEIN 4; MEMBRANE PROTEIN; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOLOCALIZATION; PROTEIN PROTEIN INTERACTION; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; CELL MEMBRANE; CONFOCAL MICROSCOPY; METABOLISM;

ANTIGENS, CD31; BLOTTING, WESTERN; CELL MEMBRANE; FATTY ACID-BINDING PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL;

EID: 84920730847     PISSN: 02149168     EISSN: 15781879     Source Type: Journal    
DOI: 10.1016/j.arteri.2014.05.003     Document Type: Article

References (32)

1. Zimmerman A.W., Veerkamp J.H. New insights into the structure and function of fatty acid-binding proteins. Cell Mol Life Sci 2002, 59:1096-1116.
2. Hertzel A.V., Bernlohr D.A. The mammalian fatty acid-binding protein multigene family: Molecular and genetic insights into function. Trends Endocrinol Metab 2000, 11:175-180.
3. Bernlohr D.A., Simpson M.A., Hertzel A.V., Banaszak L.J. Intracellular lipid-binding proteins and their genes. Annu Rev Nutr 1997, 17:277-303.
4. Haunerland N.H., Spener F. Fatty acid-binding proteins - insights from genetic manipulations. Prog Lipid Res 2004, 43:328-349.
5. Makowski L., Hotamisligil G.S. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005, 16:543-548.
6. Wolfrum C. Cytoplasmic fatty acid binding protein sensing fatty acids for peroxisome proliferator activated receptor activation. Cell Mol Life Sci 2007, 64:2465-2476.
7. Jenkins-Kruchten A.E., Bennaars-Eiden A., Ross J.R., Shen W.J., Kraemer F.B., Bernlohr D.A. Fatty acid-binding protein-hormone-sensitive lipase interaction. Fatty acid dependence on binding. J Biol Chem 2003, 278:47636-47643.
8. Thompson B.R., Mazurkiewicz-Munoz A.M., Suttles J., Carter-Su C., Bernlohr D.A. Interaction of adipocyte fatty acid-binding protein (AFABP) and JAK2: AFABP/aP2 as a regulator of JAK2 signaling. J Biol Chem 2009, 284:13473-13480.
9. Gorbenko O., Panayotou G., Zhyvoloup A., Volkova D., Gout I., Filonenko V. Identification of novel PTEN-binding partners: PTEN interaction with fatty acid binding protein FABP4. Mol Cell Biochem 2010, 337:299-305.
10. Elmasri H., Karaaslan C., Teper Y., Ghelfi E., Weng M., Ince T.A., et al. Fatty acid binding protein 4 is a target of VEGF and a regulator of cell proliferation in endothelial cells. Faseb J 2009, 23:3865-3873.
11. Scheja L., Makowski L., Uysal K.T., Wiesbrock S.M., Shimshek D.R., Meyers D.S., et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/- mice. Diabetes 1999, 48:1987-1994.
12. Cabre A., Lazaro I., Cofan M., Jarauta E., Plana N., Garcia-Otin A.L., et al. FABP4 plasma levels are increased in familial combined hyperlipidemia. J Lipid Res 2010, 51:1173-1178.
13. Cabre A., Lazaro I., Girona J., Manzanares J.M., Marimon F., Plana N., et al. Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. Atherosclerosis 2007, 195:e150-e158.
14. Cabre A., Lazaro I., Girona J., Manzanares J.M., Marimon F., Plana N., et al. Plasma fatty acid-binding protein 4 increases with renal dysfunction in type 2 diabetic patients without microalbuminuria. Clin Chem 2008, 54:181-187.
15. Cabre A., Lazaro I., Girona J., Manzanares J.M., Marimon F., Plana N., et al. Plasma fatty acid binding protein 4 is associated with atherogenic dyslipidemia in diabetes. J Lipid Res 2008, 49:1746-1751.
16. Coll B., Cabre A., Alonso-Villaverde C., Lazaro I., Aragones G., Parra S., et al. The fatty acid binding protein-4 (FABP4) is a strong biomarker of metabolic syndrome and lipodystrophy in HIV-infected patients. Atherosclerosis 2008, 199:147-153.
17. Stejskal D., Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: A new marker of metabolic syndrome?. Eur J Clin Invest 2006, 36:621-625.
18. Xu A., Wang Y., Xu J.Y., Stejskal D., Tam S., Zhang J., et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006, 52:405-413.
19. Tso A.W., Xu A., Sham P.C., Wat N.M., Wang Y., Fong C.H., et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: A 10-year prospective study in a Chinese cohort. Diabetes Care 2007, 30:2667-2672.
20. Xu A., Tso A.W., Cheung B.M., Wang Y., Wat N.M., Fong C.H., et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: A 5-year prospective study. Circulation 2007, 115:1537-1543.
21. Yeung D.C., Xu A., Cheung C.W., Wat N.M., Yau M.H., Fong C.H., et al. Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:1796-1802.
22. Lamounier-Zepter V., Look C., Alvarez J., Christ T., Ravens U., Schunck W.H., et al. Adipocyte fatty acid-binding protein suppresses cardiomyocyte contraction: A new link between obesity and heart disease. Circ Res 2009, 105:326-334.
23. Agardh H.E., Folkersen L., Ekstrand J., Marcus D., Swedenborg J., Hedin U., et al. Expression of fatty acid-binding protein 4/aP2 is correlated with plaque instability in carotid atherosclerosis. J Intern Med 2011, 269:200-210.
24. Peeters W., de Kleijn D.P., Vink A., van de Weg S., Schoneveld A.H., Sze S.K., et al. Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. Eur Heart J 2011, 32:1758-1768.
25. Aragones G., Ferre R., Lazaro I., Cabre A., Plana N., Merino J., et al. Fatty acid-binding protein 4 is associated with endothelial dysfunction in patients with type 2 diabetes. Atherosclerosis 2010, 213:329-331.
26. Aragones G., Saavedra P., Heras M., Cabre A., Girona J., Masana L. Fatty acid-binding protein 4 impairs the insulin-dependent nitric oxide pathway in vascular endothelial cells. Cardiovasc Diabetol 2012, 11:72.
27. Girona J., Rosales R., Plana N., Saavedra P., Masana L., Vallve J.C. FABP4 induces vascular smooth muscle cell proliferation and migration through a MAPK-dependent pathway. PLoS One 2013, 8:e81914.
28. Glass R., Loesch A., Bodin P., Burnstock G. P2X4 and P2X6 receptors associate with VE-cadherin in human endothelial cells. Cell Mol Life Sci 2002, 59:870-881.
29. Klockenbusch C., Kast J. Optimization of formaldehyde cross-linking for protein interaction analysis of non-tagged integrin beta1. J Biomed Biotechnol 2010, 2010:927585.
30. Vasilescu J., Guo X., Kast J. Identification of protein-protein interactions using in vivo cross-linking and mass spectrometry. Proteomics 2004, 4:3845-3854.
31. Burton P.B., Hogben C.E., Joannou C.L., Clark A.G., Hsuan J.J., Totty N.F., et al. Heart fatty acid binding protein is a novel regulator of cardiac myocyte hypertrophy. Biochem Biophys Res Commun 1994, 205:1822-1828.
32. Hresko R.C., Hoffman R.D., Flores-Riveros J.R., Lane M.D. Insulin receptor tyrosine kinase-catalyzed phosphorylation of 422(aP2) protein. Substrate activation by long-chain fatty acid. J Biol Chem 1990, 265:21075-21085.